The delisting from the CSE is a routine cost-saving measure with no expected impact on Nasdaq liquidity or operations. Monitor for any future Nasdaq compliance issues, as the company now relies solely on that exchange for its primary listing.
Price Chart
Executive Summary
Quantum BioPharma announced plans to voluntarily delist its Class B subordinate voting shares from the Canadian Securities Exchange (CSE), with the last trading day expected to be September 4, 2026, subject to CSE approval. The delisting is a cost-cutting measure to consolidate trading liquidity onto the Nasdaq, where the shares will continue trading under the symbol QNTM. This is a routine administrative move with no material impact on the company's operations or Nasdaq listing status.
Key Facts
- Quantum BioPharma applied to voluntarily delist its Class B Shares from the Canadian Securities Exchange (CSE).
- The last trading day on the CSE is expected to be September 4, 2026, subject to CSE approval.
- The delisting will not affect the company's listing on Nasdaq, the Frankfurt Stock Exchange, or Upstream.
- The company cited low trading volume on the CSE and the desire to consolidate trading into a single principal marketplace on Nasdaq.
- The company will remain a reporting issuer in Canadian jurisdictions and continue filing on SEDAR+ and EDGAR.
Financial Impact
No financial figures were provided in the filing. The delisting is expected to reduce expenses, administrative efforts, and regulatory burdens associated with maintaining a dual listing.
Risk Factors
- Risk that CSE does not approve the delisting application or approves it on different terms.
- Risk that the anticipated benefits of the delisting (reduced costs, improved liquidity) are not realized.
- Risk that Canadian shareholders face difficulties or additional costs trading on Nasdaq.
- Risk that Nasdaq becomes the company's only principal trading market and the company subsequently fails to satisfy Nasdaq continued listing requirements, including the minimum bid price requirement.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001185185-26-003794 |
| Document: qntm6k090126.htm | 0001185185-26-003794 |
| Document: 0001185185-26-003794-index-headers.html | 0001185185-26-003794 |
| Document: 0001185185-26-003794-index.html | 0001185185-26-003794 |
| Document: 0001185185-26-003794.txt | 0001185185-26-003794 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 8, 2026 18d ago | 6-K | $3.11 | awaiting T+20 | — | $2.24 (−27.97%) |
Oct 6, 2026 20d ago | 6-K | $3.09 | awaiting T+20 | — | $2.24 (−27.51%) |
Oct 6, 2026 20d ago | Press Release | $3.09 | awaiting T+20 | — | $2.24 (−27.51%) |
Oct 5, 2026 21d ago | SC 13G/A | $3.27 | awaiting T+20 | — | $2.24 (−31.50%) |
Sep 24, 2026 4w ago | 6-K | $4.00 $2.27 | ▼ −43.25% | ▼ −42.83% | $2.24 (−44.00%) |
Sep 17, 2026 5w ago | 6-K | $3.72 $2.71 | ▼ −27.15% | ▼ −28.36% | $2.24 (−39.78%) |
Sep 17, 2026 5w ago | 6-K | $3.72 $2.71 | ▼ −27.15% | ▼ −28.36% | $2.24 (−39.78%) |
Sep 15, 2026 5w ago | 6-K | $3.46 $2.89 | ▼ −16.47% | ▼ −19.45% | $2.24 (−35.26%) |
Sep 1, 2026 7w ago | 6-K | $3.08 $3.60 | ▲ +16.88% | ▲ +17.21% | $2.24 (−27.27%) |
Sep 1, 2026 7w ago | Press Release | $3.08 $3.60 | ▲ +16.88% | ▲ +17.21% | $2.24 (−27.27%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers